235 related articles for article (PubMed ID: 15841634)
81. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
[TBL] [Abstract][Full Text] [Related]
82. Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
Shulstad RM
Dermatol Nurs; 2009; 21(2):86-7. PubMed ID: 19507375
[TBL] [Abstract][Full Text] [Related]
83. Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas.
Berman B
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s3-6. PubMed ID: 18277456
[TBL] [Abstract][Full Text] [Related]
84. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
85. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.
Eigentler TK; Kamin A; Weide BM; Breuninger H; Caroli UM; Möhrle M; Radny P; Garbe C
J Am Acad Dermatol; 2007 Oct; 57(4):616-21. PubMed ID: 17610993
[TBL] [Abstract][Full Text] [Related]
86. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
87. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
88. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Maus J; Munzel U
Eur J Dermatol; 2008; 18(6):677-82. PubMed ID: 18955210
[TBL] [Abstract][Full Text] [Related]
89. Treatment of various types of basal cell carcinoma with topical 5% imiquimod in the elderly who refused surgical intervention: a case series.
Kaçar SD; Özuğuz P; Erkan F; Karaca Ş
J Dermatolog Treat; 2015 Apr; 26(2):165-7. PubMed ID: 24731081
[TBL] [Abstract][Full Text] [Related]
90. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
91. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Wagstaff AJ; Perry CM
Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
[TBL] [Abstract][Full Text] [Related]
92. Nodular basal cell carcinoma: when in doubt, cut it out.
Brownell I
J Drugs Dermatol; 2007 Dec; 6(12):1245-6. PubMed ID: 18189068
[TBL] [Abstract][Full Text] [Related]
93. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.
Célestin Schartz NE; Chevret S; Paz C; Kerob D; Verola O; Morel P; Lebbé C
J Am Acad Dermatol; 2008 Apr; 58(4):585-91. PubMed ID: 18068265
[TBL] [Abstract][Full Text] [Related]
94. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
95. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod.
Messeguer F; Serra-Guillen C; Echeverria B; Requena C; Sanmartin O; Llombart B; Guillen C; Nagore E
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):879-81. PubMed ID: 21752102
[TBL] [Abstract][Full Text] [Related]
96. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma.
Graells J; Ojeda RM; García-Cruz A
Actas Dermosifiliogr; 2014; 105(1):53-9. PubMed ID: 24139468
[TBL] [Abstract][Full Text] [Related]
97. Successful treatment of basal cell carcinoma on the face with imiquimod 5% cream.
Oster-Schmidt C; Altmeyer P; Stücker M
Acta Derm Venereol; 2002; 82(6):477. PubMed ID: 12575864
[No Abstract] [Full Text] [Related]
98. Nonsyndromic multiple basal cell carcinomas successfully treated with imiquimod 5% cream.
Kocabaş E; Ermertcan AT; Bilaç C; Bilaç DB; Temiz P
Cutan Ocul Toxicol; 2010 Dec; 29(4):300-2. PubMed ID: 20684662
[TBL] [Abstract][Full Text] [Related]
99. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
[No Abstract] [Full Text] [Related]
100. Imiquimod to treat different cancers of the epidermis.
Eklind J; Tartler U; Maschke J; Lidbrink P; Hengge UR
Dermatol Surg; 2003 Aug; 29(8):890-6; discussion 896. PubMed ID: 12859398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
